Provided by Tiger Trade Technology Pte. Ltd.

Lipocine

9.96
-0.0400-0.40%
Post-market: 9.960.00000.00%16:10 EST
Volume:327.00K
Turnover:3.23M
Market Cap:55.30M
PE:-9.76
High:10.46
Open:9.97
Low:9.61
Close:10.00
52wk High:12.37
52wk Low:2.52
Shares:5.55M
Float Shares:5.39M
Volume Ratio:1.86
T/O Rate:6.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0204
EPS(LYR):-0.0016
ROE:-32.92%
ROA:-21.45%
PB:3.91
PE(LYR):-6,129.23

Loading ...

Lipocine Updates Corporate Presentation for Investors

TIPRANKS
·
Nov 18, 2025

Lipocine Reports Positive Interim Safety Results in Phase 3 Trial of Oral PPD Treatment

Reuters
·
Nov 18, 2025

Lipocine Inc: Topline Results Are on Track for Q2 of 2026

THOMSON REUTERS
·
Nov 18, 2025

Lipocine Inc: per Drug Safety Monitoring Board (Dsmb) Meeting Evaluating One-Third of Planned Participants, Study to Continue as Planned

THOMSON REUTERS
·
Nov 18, 2025

Lipocine Inc - No Dose Reductions or Drug-Related Saes Reported

THOMSON REUTERS
·
Nov 18, 2025

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of Lpcn 1154 in Postpartum Depression (Ppd)

THOMSON REUTERS
·
Nov 18, 2025

Lipocine Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 13, 2025

Lipocine (LPCN) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Nov 13, 2025

Lipocine (LPCN) Gets a Buy from Alliance Global Partners

TIPRANKS
·
Nov 08, 2025

Lipocine Inc. Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 07, 2025

Lipocine Q3 EPS $(0.59) Misses $(0.55) Estimate, Sales $114.574K Miss $238.000K Estimate

Benzinga
·
Nov 06, 2025

Lipocine posts Q3 net loss of $3.2 million on $831,000 revenue

Reuters
·
Nov 06, 2025

BRIEF-Lipocine Q3 EPS USD -0.59

Reuters
·
Nov 06, 2025

Press Release: Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Dow Jones
·
Nov 06, 2025

Lipocine Presents Promising LPCN 2401 Data at ObesityWeek

TIPRANKS
·
Nov 04, 2025

Lipocine Reports LPCN 2401 Rapidly Improves Body Composition and Liver Health in Obese Men

Reuters
·
Nov 04, 2025

Lipocine Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
Nov 03, 2025

BRIEF-Lipocine Provides Progress Update On LPCN 1154 Phase 3 Clinical

Reuters
·
Sep 30, 2025

Lipocine Inc: Dsmb Safety Review Update Planned for 4Q 2025

THOMSON REUTERS
·
Sep 30, 2025

Lipocine Inc - Topline Results Anticipated in Second Quarter of 2026

THOMSON REUTERS
·
Sep 30, 2025